ZNRF2 and breast carcinoma: In addition, the correlation between low levels of ZNRF2 and poor OS (p = 0.00047), Postprogression survival (PPS) (p = 7.3e‐05) for lung cancer (Figure S5B), and poor OS (p = 7.2e‐08), FP (p = 1.5e‐06), PPS (p = 3.5e‐06) for gastric cancer (Figure S5C), and poor OS (p = 0.00014), DMFS (Distant metastasis‐free survival) (p = 0.011), PPS (p = 0.022), RFS (Relapse‐free survival) (p = 4.7e‐05) for breast cancer (Figure S5D) and poor OS (p = 0.005) for liver cancer (Figure S5E) prognosis were observed, respectively.